MedTrace Logo

Trazodone vs. Quetiapine for the Treatment of ICU Delirium

NCT05307003 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 10

Last updated 2026-05-04

No results posted yet for this study

Summary

This is a single-center, prospective observational pilot study. The objective of this study is to evaluate the effectiveness of trazodone as compared to quetiapine, in the management of ICU delirium in adult (\>=18 years old) surgical and medical ICU patients. The investigators will compare outcomes such as delirium duration, delirium-free days, coma-free days, in-hospital mortality, 28-day mortality, hospital length of stay (LOS), ICU LOS, mechanical ventilator days, complications, adverse effects, rescue medication use, delirium symptom severity, sleep duration, and sleep quality among participants receiving trazodone or quetiapine. The investigators hypothesize participants receiving trazodone will be associated with a shorter duration of delirium, decreased delirium severity, and improved sleep quality compared to participants receiving quetiapine.

Conditions

  • Delirium
  • Delirium of Mixed Origin
  • Delirium, Sepsis Associated
  • Delirium in Old Age
  • Delirium Confusional State
  • Psych
  • Morality
  • Treatment Side Effects

Interventions

DRUG

Trazodone

Medication used to treat ICU delirium

DRUG

Quetiapine

Medication used to treat ICU delirium

Sponsors & Collaborators

  • University of Southern California

    lead OTHER

Principal Investigators

  • Catherine Kuza, MD, FASA · Keck School of Medicine of the University of Southern California

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-01
Primary Completion
2024-06-01
Completion
2024-06-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05307003 on ClinicalTrials.gov